SOURCE: TopiVert Pharma Limited

May 09, 2016 02:00 ET

TopiVert to Present First in Human Data From Its Phase I Clinical Study With TOP1288 at DDW 2016 in San Diego

LONDON, UNITED KINGDOM--(Marketwired - May 9, 2016) - TopiVert Pharma Ltd ("TopiVert" or the "Company"), a clinical-stage biotechnology company developing Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, locally-acting medicines for the treatment of chronic inflammatory diseases of the gastrointestinal tract and eye, announces that it will present posters on the Phase I study data results and pre-clinical pharmacology for TOP1288, its lead compound for the treatment of ulcerative colitis (UC), a form of inflammatory bowel disease (IBD), at the Digestive Disease Week (DDW) 2016 in San Diego, California, from 21-24 May.

Senior members of the management and R&D teams will be available at the conference to discuss the data with interested parties. The posters to be presented are:

  • A first-in-human randomized double-blind placebo-controlled clinical trial of a novel narrow spectrum kinase inhibitor. Rowley et al.
  • TOP1210 NSKI Demonstrates Superior Activity and Improved Safety Profile Potential Compared to Corticosteroid and Immunomodulators in Preclinical Models of Colitis. Walshe et al.
  • Inhibition of cytokine release from HT-29 cells and ulcerative colitis biopsies is potentiated by combination of selective kinase inhibitors and such effects are mimicked by TOP1210, a Narrow spectrum kinase inhibitor (NSKI). Foster et al.
  • Effects of TOP1210, a narrow spectrum kinase inhibitor, and selective kinase inhibitors on the intestinal pro-inflammatory immune response in ulcerative colitis. Foster et al.

The posters are all available at www.topivert.com/our-science-publications

Click on, or paste the following link into your web browser, to view the associated PDF document.

http://www.rns-pdf.londonstockexchange.com/rns/5852X_1-2016-5-9.pdf

-Ends-

This information is provided by RNS
The company news service from the London Stock Exchange

Contact Information

  • Contact:
    TopiVert Pharma Ltd
    info@topivert.com
    Steve Webber
    Chief Scientific Officer
    +44 (0)20 3763 9468
    Nick Staples
    Business and Corporate Development
    +44 (0)7818 075 816

    Consilium Strategic Communications
    topivert@consilium-comms.com
    Mary-Jane Elliott / Ivar Milligan / Hendrik Thys
    +44 (0)20 3709 5700